Story

Apnimed Stock Climbs Over 10% as Wall Street Initiates Bullish Coverage

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Apnimed Stock Climbs Over 10% as Wall Street Initiates Bullish Coverage
Text size
Background

Shares of Apnimed Inc. (NASDAQ:APMD) jumped 10.3% on Tuesday after several Wall Street analysts initiated coverage on the biotechnology company with bullish outlooks. The positive ratings centered on the commercial potential of Apnimed's lead drug candidate for obstructive sleep apnea (OSA).

Wave of Positive Ratings

At least four investment firms began covering Apnimed, signaling growing investor interest in the company's pipeline. The new ratings and price targets include:

  • Cantor Fitzgerald: Initiated with an Overweight rating and a $60 price target.
  • BofA Securities: Initiated with a Buy rating and a $41 price target.
  • LifeSci Capital: Initiated with an Outperform rating and a $50 price target.
  • Evercore ISI: Initiated with an Outperform rating.

Cantor Fitzgerald analyst Josh Schimmer's price target, based on a discounted cash flow analysis, represents nearly double the stock's Tuesday trading price of around $32, according to the firm's note.

Focus on Sleep Apnea Drug Oxnimbi

Sample IUX Markets – In-articleAd

The analysts' optimism is focused on Oxnimbi, Apnimed's investigational oral treatment for obstructive sleep apnea. The drug is a combination pill of oxybutynin and atomoxetine designed to address the underlying cause of OSA, a condition where the upper airway collapses during sleep, leading to obstructed breathing.

According to Cantor Fitzgerald, Oxnimbi works by "increasing muscle tone during deep sleep," which prevents airway collapse. The therapy has a Prescription Drug User Fee Act (PDUFA) target action date with the FDA set for February 28, 2027.

Sizing the Market Opportunity

Analysts highlighted the significant unmet need in the OSA market. BofA Securities analyst Jason Gerberry pointed to a large initial opportunity among an estimated 10.5 million patients in the U.S. who have been diagnosed but remain untreated.

Gerberry's thesis rests on Oxnimbi's differentiated mechanism compared to existing treatments, positive Phase 3 data that showed significant reductions in breathing interruptions, and the large patient population. BofA Securities models potential peak U.S. sales of approximately $2 billion on a nominal basis and $1.7 billion on a risk-adjusted basis.

Read next

More on Stocks
Back to latest news

LATEST